ProstaPilot: A Comparative Study of Biparametric Magnetic
Resonance Imaging Versus Prostate-specific Antigen as a
Screening Test for Prostate Cancer

J 2025

ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer

STANÍK, Michal; Michal STANDARA; David MIKLÁNEK; Kateřina HEJCMANOVÁ; Milos PACAL et. al.

Basic information

Original name

ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer

Authors

STANÍK, Michal (703 Slovakia, belonging to the institution); Michal STANDARA (203 Czech Republic); David MIKLÁNEK (203 Czech Republic, belonging to the institution); Kateřina HEJCMANOVÁ (203 Czech Republic, belonging to the institution); Milos PACAL (203 Czech Republic); Roman HRABEC (203 Czech Republic, belonging to the institution); Ondřej NGO (203 Czech Republic, belonging to the institution); Karel HEJDUK (203 Czech Republic, belonging to the institution); Jan KRISTEK (203 Czech Republic); Michal UHER (203 Czech Republic); Ondřej MÁJEK (203 Czech Republic, belonging to the institution) and Alexandr POPRACH (203 Czech Republic, belonging to the institution)

Edition

EUROPEAN UROLOGY OPEN SCIENCE, AMSTERDAM, ELSEVIER, 2025, 2666-1691

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30204 Oncology

Country of publisher

Netherlands

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 3.200 in 2023

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.euros.2025.03.016

UT WoS

001477738200001

EID Scopus

2-s2.0-105003112819

Keywords in English

Prostate cancer; Screening; Prostate-specific antigen; Magnetic resonance imaging

Abstract

V originále

Background and objective: Our aim was to compare detection rates for clinically significant prostate cancer (csPC) between biparametric magnetic resonance imaging (bpMRI) and prostate-specific antigen (PSA) screening pathways in the Czech population, which has a high prevalence of opportunistic PSA testing (45% in the Methods: Between May 2022 and May 2023, 423 men aged 50-69 yr who were enrolled via volunteer-based recruitment, underwent both PSA testing and bpMRI of the prostate. Positive results were defined as PSA >= 3lg/l or a Prostate Imaging-Reporting and Data System score of 4-5. Those with positive tests were referred for further evaluation, including an MRI-targeted biopsy and a systematic 12-core biopsy. csPC was defined as any cancer of International Society of Key findings and limitations: Of the 423 men, 35 (8.3%) had at least one positive screening test. The PSA-based pathway identified 25 men (5.9%), whereas the MRI-based pathway identified 16 (3.8%) with suspicion of PC, with potential to reduce the number of biopsies required by 36%. Subsequent biopsy revealed PC in seven men (1.7%) with a positive PSA test and 14 men (3.3%) with positive MRI findings. Nonsignificant PC and csPC rates were 1.0% (n = 4) and 0.7% (n = 3) for the PSA pathway, and 1.7% and 1.7% (n = 7) for the MRI pathway, respectively. Conclusions and clinical implications: In a highly prescreened population, bpMRI may increase the csPC detection rate while reducing the number of biopsies needed in comparison to PSA-based diagnosis. However, bpMRI may also slightly increase the detection of grade group 1 cancers. Patient summary: We compared a blood test for PSA (prostate-specific antigen) and an MRI scan (magnetic resonance imaging) for detection of prostate cancer in men aged 50-69 years. We found that MRI scans may reduce the number of biopsies that need to be performed for cancer diagnosis while increasing the detection rate for cancers that are significant. (c) 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).

Links

LM2023050, research and development project

Name: Národní infrastruktura pro biologické a medicínské zobrazování

Investor: Ministry of Education, Youth and Sports of the CR, Czech BioImaging: National research infrastructure for biological and medical imaging

NU22-09-00539, research and development project

Name: ProstaPilot. Screening karcinomu prostaty pomocí magnetické rezonance se zkráceným protokolem

Investor: Ministry of Health of the CR, ProstaPilot. Prostate cancer screening with abbreviated MRI protocol, Subprogram 1 - standard

Cite

STANÍK, Michal; Michal STANDARA; David MIKLÁNEK; Kateřina HEJCMANOVÁ; Milos PACAL; Roman HRABEC; Ondřej NGO; Karel HEJDUK; Jan KRISTEK; Michal UHER; Ondřej MÁJEK and Alexandr POPRACH. ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer. EUROPEAN UROLOGY OPEN SCIENCE. AMSTERDAM: ELSEVIER, 2025, vol. 76, June 2025, p. 7-13. ISSN 2666-1691. Available from: https://dx.doi.org/10.1016/j.euros.2025.03.016.

@article{2500960,
   author = {Staník, Michal and Standara, Michal and Miklánek, David and Hejcmanová, Kateřina and Pacal, Milos and Hrabec, Roman and Ngo, Ondřej and Hejduk, Karel and Kristek, Jan and Uher, Michal and Májek, Ondřej and Poprach, Alexandr},
   article_location = {AMSTERDAM},
   article_number = {June 2025},
   doi = {http://dx.doi.org/10.1016/j.euros.2025.03.016},
   keywords = {Prostate cancer; Screening; Prostate-specific antigen; Magnetic resonance imaging},
   language = {eng},
   issn = {2666-1691},
   journal = {EUROPEAN UROLOGY OPEN SCIENCE},
   title = {ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer},
   url = {https://www.sciencedirect.com/science/article/pii/S2666168325001041?via%3Dihub},
   volume = {76},
   year = {2025}
}

TY  - JOUR
ID  - 2500960
AU  - Staník, Michal - Standara, Michal - Miklánek, David - Hejcmanová, Kateřina - Pacal, Milos - Hrabec, Roman - Ngo, Ondřej - Hejduk, Karel - Kristek, Jan - Uher, Michal - Májek, Ondřej - Poprach, Alexandr
PY  - 2025
TI  - ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer
JF  - EUROPEAN UROLOGY OPEN SCIENCE
VL  - 76
IS  - June 2025
SP  - 7-13
EP  - 7-13
PB  - ELSEVIER
SN  - 26661691
KW  - Prostate cancer
KW  - Screening
KW  - Prostate-specific antigen
KW  - Magnetic resonance imaging
UR  - https://www.sciencedirect.com/science/article/pii/S2666168325001041?via%3Dihub
N2  - Background and objective: Our aim was to compare detection rates for clinically significant prostate cancer (csPC) between biparametric magnetic resonance imaging (bpMRI) and prostate-specific antigen (PSA) screening pathways in the Czech population, which has a high prevalence of opportunistic PSA testing (45% in the Methods: Between May 2022 and May 2023, 423 men aged 50-69 yr who were enrolled via volunteer-based recruitment, underwent both PSA testing and bpMRI of the prostate. Positive results were defined as PSA >= 3lg/l or a Prostate Imaging-Reporting and Data System score of 4-5. Those with positive tests were referred for further evaluation, including an MRI-targeted biopsy and a systematic 12-core biopsy. csPC was defined as any cancer of International Society of Key findings and limitations: Of the 423 men, 35 (8.3%) had at least one positive screening test. The PSA-based pathway identified 25 men (5.9%), whereas the MRI-based pathway identified 16 (3.8%) with suspicion of PC, with potential to reduce the number of biopsies required by 36%. Subsequent biopsy revealed PC in seven men (1.7%) with a positive PSA test and 14 men (3.3%) with positive MRI findings. Nonsignificant PC and csPC rates were 1.0% (n = 4) and 0.7% (n = 3) for the PSA pathway, and 1.7% and 1.7% (n = 7) for the MRI pathway, respectively. Conclusions and clinical implications: In a highly prescreened population, bpMRI may increase the csPC detection rate while reducing the number of biopsies needed in comparison to PSA-based diagnosis. However, bpMRI may also slightly increase the detection of grade group 1 cancers. Patient summary: We compared a blood test for PSA (prostate-specific antigen) and an MRI scan (magnetic resonance imaging) for detection of prostate cancer in men aged 50-69 years. We found that MRI scans may reduce the number of biopsies that need to be performed for cancer diagnosis while increasing the detection rate for cancers that are significant. (c) 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
ER  -

STANÍK, Michal; Michal STANDARA; David MIKLÁNEK; Kateřina HEJCMANOVÁ; Milos PACAL; Roman HRABEC; Ondřej NGO; Karel HEJDUK; Jan KRISTEK; Michal UHER; Ondřej MÁJEK and Alexandr POPRACH. ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer. \textit{EUROPEAN UROLOGY OPEN SCIENCE}. AMSTERDAM: ELSEVIER, 2025, vol.~76, June 2025, p.~7-13. ISSN~2666-1691. Available from: https://dx.doi.org/10.1016/j.euros.2025.03.016.

Přehled o publikaci